Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1424.

https://doi.org/10.1182/blood-2019-122890

Published: 2019

Journal Articles

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Muhned Alhumaid, MD, Georgina S Daher-Reyes, MD, Wilson Lam, MD, Arjun Law, MDDM, Tracy Murphy, MDFRCP,FRCPath, Caroline J McNamara, MBBS, Gil Yerushalmi, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Dawn Maze, MDFRCPC,MSc, Eshetu G Atenafu, M.Sc., P.Stat, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 2609.

https://doi.org/10.1182/blood-2019-125449

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Blood (2019) 134 (Supplement_1): 5725.

https://doi.org/10.1182/blood-2019-129078

Published: 2019

Journal Articles

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 3317.

https://doi.org/10.1182/blood-2019-125780

Published: 2019

Journal Articles

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib

Ruiqi Chen, MSc, Xing Liu, PharmD, Solaf Kanfar, MD, Dawn Maze, MDFRCPC,MSc, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, Anna Xu, Umberto Falcone, MD, Jack Seki, PharmD, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 1303.

https://doi.org/10.1182/blood-2019-124117

Published: 2019

Journal Articles

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

Blood (2017) 130 (Supplement 1): 2596.

https://doi.org/10.1182/blood.V130.Suppl_1.2596.2596

Published: 2017

Journal Articles

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

Jonathan Wang, MASc, Andre C. Schuh, MD FRCPC, Deanna Wu, MBA, Christopher N. Bredeson, MD MSc, FRCPC, Jacinta Meharchand, MD FRCPC, Lisa Favell, MBA, Louis Fu, MISt, Kelly J. Woltman, MA, C. Tom Kouroukis, MDMSc,FRCPC

Blood (2017) 130 (Supplement 1): 3397.

https://doi.org/10.1182/blood.V130.Suppl_1.3397.3397

Published: 2017

Journal Articles

A Retrospective Study of Venous Thromboembolism in Acute Leukemia Patients during Prolonged Hospital Stay. the Princess Margaret Cancer Centre Experience

Hassan Sibai, MD, Umberto Falcone, MD PhD, Arjun Datt Law, MBBS,MDDM, Ali Hosni, MD, Carmen Tan, Naoko Sakurai, Phm, MSc, Andre C. Schuh, MD FRCPC, Mark D. Minden, MD PhD, Steven M. Chan, MD PhD, Karen W.L. Yee, MD, Vikas Gupta, MD FRCP, FRCPath, Aaron D. Schimmer, MD PhD, Jack T Seki, PharmD

Blood (2016) 128 (22): 2615.

https://doi.org/10.1182/blood.V128.22.2615.2615

Published: 2016

Journal Articles

Anticoagulation Prophylaxis in Asparaginase-Based Therapy in Adults with Acute Lymphoblastic Leukemia

Hassan Sibai, MD, Umberto Falcone, MD PhD, Arjun Datt Law, MBBS,MDDM, Naoko Sakurai, Phm, MSc, Lalit Saini, MD, Tian Q Wang, Andrew Stessman, Joseph Samuel, Eshetu G. Atenafu, Ali Hosni, MD, Andre C. Schuh, MD FRCPC, Karen W.L. Yee, MD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Steven M. Chan, MD PhD, Aaron D. Schimmer, MD PhD, Joseph M. Brandwein, MD FRCPC, Jack T Seki, PharmD

Blood (2016) 128 (22): 1453.

https://doi.org/10.1182/blood.V128.22.1453.1453

Published: 2016

Journal Articles

Aplastic Anemia in Pregnancy - a Single Centre, North American Case Series

Kelly E McGowan, MD FRCPC, Ann Kinga Malinowski, MD MSc, FRCSC, Andre C. Schuh, MD FRCPC, Nadine Shehata, MD MSC

Blood (2016) 128 (22): 3909.

https://doi.org/10.1182/blood.V128.22.3909.3909

Published: 2016

Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong

Blood (2016) 128 (22): 222.

https://doi.org/10.1182/blood.V128.22.222.222

Published: 2016

Journal Articles

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Arjun Datt Law, MBBS, MDDM, Mahadeo A. Sukhai, BSc, MSc, PhD, Mariam Thomas, PhD, Andrea Arruda, MSc., Narmin Ibrahimova, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Hassan Sibai, MD, Karen W.L. Yee, MD, Dwayne L. Barber, PhD, Tracy L. Stockley, PhD, Suzanne Kamel-Reid, PhD DABMG, FACMG, Andre C. Schuh, MD FRCPC

Blood (2016) 128 (22): 2886.

https://doi.org/10.1182/blood.V128.22.2886.2886

Published: 2016

Journal Articles

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Sara Farshchi Zarabi, MD, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Mark D. Minden, MD PhD, Amr Rostom, MD, Anna Rydlewski, MD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Aaron D. Schimmer, MD PhD

Blood (2016) 128 (22): 2800.

https://doi.org/10.1182/blood.V128.22.2800.2800

Published: 2016

Journal Articles

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Blood (2016) 128 (22): 4263.

https://doi.org/10.1182/blood.V128.22.4263.4263

Published: 2016

Journal Articles

Outcomes of Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients Treated with Pediatric Multi-Agent Chemotherapy and Imatinib and the Impact of Residual Disease Monitoring on Survival

Solaf Sami Kanfar, MD, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Aaron D. Schimmer, MD PhD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2016) 128 (22): 3976.

https://doi.org/10.1182/blood.V128.22.3976.3976

Published: 2016

Journal Articles

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Justyna Bartoszko, MD, Tony Panzarella, BSc MSc, Caroline Jane McNamara, MBBS, Anthea Lau, Aaron D. Schimmer, MD PhD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Rebecca Devlin, PhD, Vikas Gupta, MD

Blood (2016) 128 (22): 4264.

https://doi.org/10.1182/blood.V128.22.4264.4264

Published: 2016

Journal Articles

Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014

Sita D. Bhella, MD, Rumina Musani, MDFCAP, FRCPC, Anna Porwit, MDPhD, Anne Tierens, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 4865.

https://doi.org/10.1182/blood.V126.23.4865.4865

Published: 2015

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

NARROW

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

A Retrospective Study of Venous Thromboembolism in Acute Leukemia Patients during Prolonged Hospital Stay. the Princess Margaret Cancer Centre Experience

Anticoagulation Prophylaxis in Asparaginase-Based Therapy in Adults with Acute Lymphoblastic Leukemia

Aplastic Anemia in Pregnancy - a Single Centre, North American Case Series

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Outcomes of Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients Treated with Pediatric Multi-Agent Chemotherapy and Imatinib and the Impact of Residual Disease Monitoring on Survival

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only